Ampio Pharmaceuticals (AMPE)
(Delayed Data from OTC)
$0.25 USD
+0.02 (8.70%)
Updated May 24, 2024 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AMPE 0.25 +0.02(8.70%)
Will AMPE be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for AMPE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AMPE
New Strong Sell Stocks for April 7th
New Strong Sell Stocks for April 1st
AMPE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for AMPE
Ampio Pharmaceuticals Received Audit Opinion with Going Concern Explanation
Biotech Alert: Searches spiking for these stocks today
AMPE Stock Earnings: Ampio Pharmaceuticals Reported Results for Q4 2023
VERI, CHEK and CZOO among mid-day movers
GOEV, NBSE and FLGC among pre-market losers